These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36684047)

  • 21. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
    Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
    J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
    [No Abstract]   [Full Text] [Related]  

  • 22. A Comparison of Single and Combined Schemes of Asia-Pacific Colorectal Screening, Faecal Immunochemical and Stool Deoxyribonucleic Acid Testing for Community Colorectal Cancer Screening.
    Ze Y; Tu H; Zhang L; Bai Y; Ren Y; Chen X; Xue Y; Sun R; Yang Y; Yang J; Zhou X; Liu L
    J Multidiscip Healthc; 2023; 16():571-586. PubMed ID: 36883167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inappropriate Multi-Target Stool DNA Use for Colorectal Cancer Screening: Risks, Compliance, and Outcomes.
    Lazar NJ; Khreisat A; AlKloub R; Al-Hillan A; Duffy M
    Cureus; 2023 Jun; 15(6):e40506. PubMed ID: 37397671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
    Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ
    Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multitarget Stool DNA Screening in Clinical Practice: High Positive Predictive Value for Colorectal Neoplasia Regardless of Exposure to Previous Colonoscopy.
    Eckmann JD; Ebner DW; Bering J; Kahn A; Rodriguez E; Devens ME; Lowrie KL; Doering K; Then S; Burger KN; Mahoney DW; Prichard DO; Wallace MB; Gurudu SR; Finney LJ; Limburg P; Berger B; Ahlquist DA; Kisiel JB
    Am J Gastroenterol; 2020 Apr; 115(4):608-615. PubMed ID: 32068535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of the Sessile Serrated Polyp Pathway on Predicted Colorectal Cancer Outcomes.
    Kisiel JB; Itzkowitz SH; Ozbay AB; Saoud L; Parton M; Lieberman D; Limburg PJ
    Gastro Hep Adv; 2022; 1(1):55-62. PubMed ID: 39129937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic Performance of Multitarget Stool DNA and CT Colonography for Noninvasive Colorectal Cancer Screening.
    Pickhardt PJ; Graffy PM; Weigman B; Deiss-Yehiely N; Hassan C; Weiss JM
    Radiology; 2020 Oct; 297(1):120-129. PubMed ID: 32779997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia.
    Lidgard GP; Domanico MJ; Bruinsma JJ; Light J; Gagrat ZD; Oldham-Haltom RL; Fourrier KD; Allawi H; Yab TC; Taylor WR; Simonson JA; Devens M; Heigh RI; Ahlquist DA; Berger BM
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1313-8. PubMed ID: 23639600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia.
    Ahlquist DA; Taylor WR; Mahoney DW; Zou H; Domanico M; Thibodeau SN; Boardman LA; Berger BM; Lidgard GP
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):272-7.e1. PubMed ID: 22019796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness.
    Berger BM; Schroy PC; Dinh TA
    Clin Colorectal Cancer; 2016 Sep; 15(3):e65-74. PubMed ID: 26792032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
    Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
    J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stool-Based Colorectal Cancer Screening Test Performance Characteristics in Those With and Without Hemorrhoids.
    Ebner DW; Rushlow D; Mou J; Porter K; Finney Rutten LJ; Limburg P; Sancar F; Imperiale TF
    Mayo Clin Proc Innov Qual Outcomes; 2023 Aug; 7(4):320-326. PubMed ID: 37502338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating Outreach Methods for Multi-Target Stool DNA Test for Colorectal Cancer Screening Among an Employer Population.
    Shepherd ME; Lecorps A; Harris-Shapiro J; Miller-Wilson LA
    J Prim Care Community Health; 2021; 12():21501327211037892. PubMed ID: 34382887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three-Year Interval for the Multi-Target Stool DNA Test for Colorectal Cancer Screening: A Longitudinal Study.
    Imperiale TF; Lavin PT; Marti TN; Jakubowski D; Itzkowitz SH; May FP; Limburg PJ; Sweetser S; Daghestani A; Berger BM
    Cancer Prev Res (Phila); 2023 Feb; 16(2):89-97. PubMed ID: 36205504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel multitarget stool DNA test for colorectal cancer screening.
    Malik P
    Postgrad Med; 2016; 128(2):268-72. PubMed ID: 26753807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What do 'false-positive' stool tests really mean? Data from the New Hampshire colonoscopy registry.
    Butterly LF; Hisey WM; Robinson CM; Limburg PJ; Kneedler BL; Anderson JC
    Prev Med Rep; 2023 Oct; 35():102309. PubMed ID: 37449002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic accuracy of multitarget stool DNA testing for colorectal cancer screening: A systematic review and meta-analysis.
    Dolatkhah R; Dastgiri S; Jafarabadi MA; Abdolahi HM; Somi MH
    Gastroenterol Hepatol; 2022 Dec; 45(10):753-766. PubMed ID: 35101601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positive Predictive Value for Multitarget Stool DNA After Bariatric and Metabolic Surgery.
    Ebner DW; Burger KN; Broderick B; Mahoney DW; Kellogg TA; Acosta A; Kisiel JB
    Gastro Hep Adv; 2023; 2(7):902-910. PubMed ID: 37876832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model.
    Piscitello A; Saoud L; Fendrick AM; Borah BJ; Hassmiller Lich K; Matney M; Ozbay AB; Parton M; Limburg PJ
    PLoS One; 2020; 15(12):e0244431. PubMed ID: 33373409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing.
    Berger BM; Parton MA; Levin B
    Am J Manag Care; 2016 Feb; 22(2):e77-81. PubMed ID: 26881323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.